Today's Date
High Dose Immunosuppression and Autologous Stem Cell Transplantation for Multiple Sclerosis
(
HALT MS
)
ITN Protocol #:
ITN033AI
Branded Name:
HALT MS
ClinicalTrials.Gov ID:
NCT00288626Treatment Protocol #:
BEAM + rATG
Therapeutic Area:
Autoimmune Disease
Current Status:
Complete
Summary:
A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis
Clinical Operations Manager
ITN Biologist
ITN Biostat
ITN Clinical Trial Physician
NIAID Project Manager
Rho Scientist
PPD Lead Monitor
Study Personnel:
